(19) United States
(12) Patent Application Publication (io) Pub. No.: US 2004/0220660 Al
Shanley et al. (43) Pub. Date: Nov. 4,2004
(54) BIORESORBABLE STENT WITH
BENEFICIAL AGENT RESERVOIRS
(76) Inventors: John F. Shanley, Redwood City, CA
(US); Frank Litvack, Los Angeles, CA
(US); Theodore L. Parker, Danville,
CA (US); Stephen Hunter Diaz, Palo
Alto, CA (US)
Correspondence Address:
CINDY A. LYNCH
CONOR MEDSYSTEMS, INC.
1003 HAMILTON COURT
MENLO PARK, CA 94025 (US)
(21) Appl. No.: 10/822,063
(22) Filed: Apr. 8, 2004
Related U.S. Application Data
(63) Continuation-in-part of application No. 10/057,414, filed on Jan. 25, 2002.
Continuation-in-part of application No. 10/777,881, filed on Feb. 11, 2004, which is a continuation-in-part of application No. 10/447,587, filed on May 28,2003.
(60) Provisional application No. 60/266,805, filed on Feb. 5,2001. Provisional application No. 60/412,489, filed on Sep. 20, 2002.
Publication Classification
(51) Int. CI.7 A61F 2/06
(52) U.S. CI 623/1.16; 623/1.42
(57) ABSTRACT
A bioresorbable drug delivery stent includes a substantially cylindrical expandable stent formed of a bioresorbable or bioresorbable material and a plurality of reservoirs or openings formed in the stent containing a beneficial agent matrix comprising a bioresorbable material and a drug. The bioresorbable stent material can be a bioresorbable metal alloy, a bioresorbable polymer, or other bioresorbable material which has sufficient structural integrity to support a lumen, such as a blood vessel lumen for a predetermined period of time. The reservoirs containing the beneficial agent matrix allow delivery of the beneficial agent, such as an antirestenotic drug, for an administration period which is generally equal to or less than a time that the bioresorbable stent is retained in the lumen. The beneficial agent matrix may include one or more bioresorbable polymers in combination with one or more therapeutic agents or drugs and the structure of the beneficial agent matrix can be programmed to achieve a desired release profile for the drug(s) and a desired administration period.
